Not in my treatment center: Leadership's perception of barriers to MOUD adoption

IF 3.7 2区 医学 Q1 PSYCHOLOGY, CLINICAL
Rebecca E. Stewart , Nicholas C. Cardamone , David S. Mandell , Nayoung Kwon , Kyle M. Kampman , Hannah K. Knudsen , Christopher W. Tjoa , Steven C. Marcus
{"title":"Not in my treatment center: Leadership's perception of barriers to MOUD adoption","authors":"Rebecca E. Stewart ,&nbsp;Nicholas C. Cardamone ,&nbsp;David S. Mandell ,&nbsp;Nayoung Kwon ,&nbsp;Kyle M. Kampman ,&nbsp;Hannah K. Knudsen ,&nbsp;Christopher W. Tjoa ,&nbsp;Steven C. Marcus","doi":"10.1016/j.jsat.2022.108900","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Despite their well-established effectiveness, medications for opioid use disorder (MOUD) are widely underutilized across the United States. In the context of a large publicly funded behavioral health system, we examined the relationship between a range of implementation barriers and a substance use disorder treatment agency's level of adoption of MOUD.</p></div><div><h3>Methods</h3><p>We surveyed leadership of publicly funded substance use disorder treatment centers in Philadelphia about the significance of barriers to implementing MOUD related to their workforce, organization, funding, regulations, and beliefs about MOUD's efficacy and safety. We queried leaders on the percentage of their patients with opioid use disorder who receive MOUD and examined associations between implementation barriers and MOUD adoption.</p></div><div><h3>Results</h3><p>Ratings of regulatory, organizational, or funding barriers of respondents who led high MOUD adopting agencies (N = 20) were indistinguishable from those who led agencies that were low adopting of MOUD (N = 23). In contrast, agency leaders who denied MOUD-belief or workforce barriers were significantly more likely to lead high-MOUD-adopting organizations.</p></div><div><h3>Conclusions</h3><p>These findings suggest that leadership beliefs about MOUD may be a key factor of the organizational decision to adopt and should be a target of implementation efforts to increase direct provision of these medications.</p></div>","PeriodicalId":17148,"journal":{"name":"Journal of Substance Abuse Treatment","volume":"144 ","pages":"Article 108900"},"PeriodicalIF":3.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Substance Abuse Treatment","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0740547222001829","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Despite their well-established effectiveness, medications for opioid use disorder (MOUD) are widely underutilized across the United States. In the context of a large publicly funded behavioral health system, we examined the relationship between a range of implementation barriers and a substance use disorder treatment agency's level of adoption of MOUD.

Methods

We surveyed leadership of publicly funded substance use disorder treatment centers in Philadelphia about the significance of barriers to implementing MOUD related to their workforce, organization, funding, regulations, and beliefs about MOUD's efficacy and safety. We queried leaders on the percentage of their patients with opioid use disorder who receive MOUD and examined associations between implementation barriers and MOUD adoption.

Results

Ratings of regulatory, organizational, or funding barriers of respondents who led high MOUD adopting agencies (N = 20) were indistinguishable from those who led agencies that were low adopting of MOUD (N = 23). In contrast, agency leaders who denied MOUD-belief or workforce barriers were significantly more likely to lead high-MOUD-adopting organizations.

Conclusions

These findings suggest that leadership beliefs about MOUD may be a key factor of the organizational decision to adopt and should be a target of implementation efforts to increase direct provision of these medications.

不是在我的治疗中心:领导层对采用mod的障碍的看法
引言尽管治疗阿片类药物使用障碍(MOUD)的药物疗效良好,但在美国各地却普遍未得到充分利用。在大型公共资助的行为健康系统的背景下,我们研究了一系列实施障碍与药物使用障碍治疗机构采用MOUD水平之间的关系,以及对MOUD疗效和安全性的信念。我们询问了领导者接受MOOD的阿片类药物使用障碍患者的百分比,并研究了实施障碍与MOOD采用之间的关系。结果领导MOOD采用率高的机构(N=20)和领导MOOD采纳率低的机构(N=23)的受访者在监管、组织或资金障碍方面的评分无法区分。相比之下,否认MOUD信仰或劳动力障碍的机构领导人更有可能领导高度采用MOUD的组织。结论这些研究结果表明,对MOUD的领导信念可能是组织决策的关键因素,并且应该是增加这些药物直接供应的实施努力的目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.60
自引率
10.30%
发文量
220
期刊介绍: The Journal of Substance Abuse Treatment (JSAT) features original reviews, training and educational articles, special commentary, and especially research articles that are meaningful to the treatment of alcohol, heroin, marijuana, and other drugs of dependence. JSAT is directed toward treatment practitioners from all disciplines (medicine, nursing, social work, psychology, and counseling) in both private and public sectors, including those involved in schools, health centers, community agencies, correctional facilities, and individual practices. The editors emphasize that JSAT articles should address techniques and treatment approaches that can be used directly by contemporary practitioners.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信